Abstract
Pruritus is a common symptom and the main source of morbidity in dermatologic diseases. Current management has been hampered by our inadequate understanding of the pathomechanisms of pruritus, but recent advances in elucidating the mediators, receptors and neuronal pathways hold promise for the development of new translational therapies. These mediators and receptors in the skin, peripheral nerves, spinal cord and brain form markers that drugs can be directed to inhibit via itch-transmitting pathways. Such targeted therapy is likely to be more effective and produce less side effects. Clinically, the treatment of pruritus should be tailored for different pruritic diseases, individualized for different patients and instituted early before the development of central sensitization. Chronic pruritus is a multidimensional problem and management requires a holistic approach, addressing the peripheral skin and neuronal pathologies, aberrant central processes and psychosocial factors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 115-121 |
| Number of pages | 7 |
| Journal | Drugs of the Future |
| Volume | 36 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 1 2011 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Perspectives in the treatment of pruritus : Focus on new strategies. / Tey, H. L.; Yosipovitch, Gil.
In: Drugs of the Future, Vol. 36, No. 2, 01.01.2011, p. 115-121.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Perspectives in the treatment of pruritus
T2 - Focus on new strategies
AU - Tey, H. L.
AU - Yosipovitch, Gil
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Pruritus is a common symptom and the main source of morbidity in dermatologic diseases. Current management has been hampered by our inadequate understanding of the pathomechanisms of pruritus, but recent advances in elucidating the mediators, receptors and neuronal pathways hold promise for the development of new translational therapies. These mediators and receptors in the skin, peripheral nerves, spinal cord and brain form markers that drugs can be directed to inhibit via itch-transmitting pathways. Such targeted therapy is likely to be more effective and produce less side effects. Clinically, the treatment of pruritus should be tailored for different pruritic diseases, individualized for different patients and instituted early before the development of central sensitization. Chronic pruritus is a multidimensional problem and management requires a holistic approach, addressing the peripheral skin and neuronal pathologies, aberrant central processes and psychosocial factors.
AB - Pruritus is a common symptom and the main source of morbidity in dermatologic diseases. Current management has been hampered by our inadequate understanding of the pathomechanisms of pruritus, but recent advances in elucidating the mediators, receptors and neuronal pathways hold promise for the development of new translational therapies. These mediators and receptors in the skin, peripheral nerves, spinal cord and brain form markers that drugs can be directed to inhibit via itch-transmitting pathways. Such targeted therapy is likely to be more effective and produce less side effects. Clinically, the treatment of pruritus should be tailored for different pruritic diseases, individualized for different patients and instituted early before the development of central sensitization. Chronic pruritus is a multidimensional problem and management requires a holistic approach, addressing the peripheral skin and neuronal pathologies, aberrant central processes and psychosocial factors.
UR - http://www.scopus.com/inward/record.url?scp=84952981902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952981902&partnerID=8YFLogxK
U2 - 10.1358/dof.2011.036.02.1543303
DO - 10.1358/dof.2011.036.02.1543303
M3 - Review article
VL - 36
SP - 115
EP - 121
JO - Drugs of the Future
JF - Drugs of the Future
SN - 0377-8282
IS - 2
ER -